You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Nov 12, 2021

PLOS ONE Article Details IL-22’s Critical Role in Mitigating ARDS

PLOS ONE, a leading international peer-reviewed scientific journal focusing on scientific and medical innovation, has published a new study that demonstrates how IL-22 plays a critical role in mitigating Acute Respiratory Distress Syndrome (ARDS) and therefore may impact the development of coronavirus disease (COVID-19). IL-22:FC (F-652), one of Evive Biotech’s key assets, is currently in development for several inflammatory disorders including COVID-19.

The publication, titled “Interleukin-22 mitigates acute respiratory distress syndrome (ARDS)”, was co-authored by Professor Jay Kolls’ team at Tulane University School of Medicine, an academic partner of Evive Biotech. Using F-652 in LPS-induced ARDS mice, the Tulane team described a previously unknown role of IL-22 in decreasing lung inflammation and lung capillary leak.

“In this study led by Dr. Sharven Taghavi, Assistant Professor of Surgery, an IL-22 dimer was shown to reduce several parameters of acute lung injury caused by bacterial endotoxin (a model of ARDS). In addition to reducing inflammation, IL-22 appears to also preserve the health of blood vessels that when damaged, may also contribute to lung injury. This data supports further investigation of IL-22 as an approach to prevent ARDS or reduce ARDS severity,” said Professor Kolls.

“This study further expands our understanding of the critical role IL-22 plays in many diseases including COVID-19,” said Dr. Simon Li, Evive Biotech’s Chief Medical Officer. “These results show that F-652 can inhibit lung inflammation and lung capillary leak in ARDS that is a common syndrome in patients with severe COVID-19. Thus, F-652 may be a novel therapy to treat ARDS and COVID-19 pneumonia.”

 The full manuscript is available at the PLOS ONE website.

 

About IL-22

IL-22 is produced by activated immune cells in response to inflammation or infection and primarily acts on epithelial cells and stroma cells through binding to its receptors selectively expressed on the surface of these cell types. Once bound to its receptors, IL-22 promotes proliferation, remodeling, and repairing of various tissues and organs to maintain innate host defense mechanisms that control the invasion of pathogens. IL-22 plays a broad role in protecting damages to barrier integrity and tissue homeostasis induced by a variety of pathogens such as viruses, bacteria, and chemicals.

About F-652

F-652 is a novel dimeric IL-22 fusion protein currently in multiple development programs for the treatment of inflammatory diseases. IL-22 has been shown to have natural growth promoting activity in epithelial cells to combat organ injuries induced by a variety of causes and eventual fatal organ failures. Published literature and Evive’s completed clinical trials have presented F-652 with opportunities to treat multiple diseases, some of which Evive is actively pursuing or developing, including acute graft vs host disease (GvHD) and acute alcoholic hepatitis.

About Evive Biotech

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com.

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

X
Share to WeChat